Alnylam Pharmaceuticals (ALNY) Accounts Payables (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Accounts Payables came in at $108.0 million in Q2 2026, up 5.49% YoY from $102.4 million in Q2 2025, and down 14.7% on a QoQ basis from $126.6 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Accounts Payables (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Accounts Payables data on file, last reported at $108.0 million in Q2 2026.
- Quarterly Accounts Payables rose 5.49% year-over-year to $108.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $108.0 million (up 5.49% YoY) and the FY2025 annual result came in at $115.7 million, up 30.88% from the prior year.
- Accounts Payables fell to $108.0 million in Q2 2026, from $126.6 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $126.6 million in Q1 2026 to a low of $40.6 million in Q3 2022.
- A 5-year average of $82.0 million and a median of $76.1 million in 2024 frame the typical range for Accounts Payables.
- The widest YoY moves for Accounts Payables: up 82.0% in 2023, down 43.4% in 2023.
- Tracing ALNY's Accounts Payables over 5 years: stood at $98.1 million in 2022, then plunged by 43.4% to $55.5 million in 2023, then soared by 59.25% to $88.4 million in 2024, then soared by 30.88% to $115.7 million in 2025, then decreased by 6.66% to $108.0 million in 2026.
- The last three Accounts Payables figures came in at $108.0 million (Q2 2026), $126.6 million (Q1 2026), and $115.7 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 25.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 108.02 Mn |
| Mar 31, 2026 | 126.63 Mn |
| Dec 31, 2025 | 115.72 Mn |
| Sep 30, 2025 | 117.59 Mn |
| Jun 30, 2025 | 102.39 Mn |
| Mar 31, 2025 | 97.40 Mn |
| Dec 31, 2024 | 88.42 Mn |
| Sep 30, 2024 | 70.81 Mn |
| Jun 30, 2024 | 73.98 Mn |
| Mar 31, 2024 | 78.15 Mn |
| Dec 31, 2023 | 55.52 Mn |
| Sep 30, 2023 | 73.84 Mn |
| Jun 30, 2023 | 59.75 Mn |
| Mar 31, 2023 | 62.24 Mn |
| Dec 31, 2022 | 98.09 Mn |
| Sep 30, 2022 | 40.57 Mn |
| Jun 30, 2022 | 52.42 Mn |
| Mar 31, 2022 | 54.92 Mn |
| Dec 31, 2021 | 73.43 Mn |
| Sep 30, 2021 | 40.05 Mn |